Macromolecular prodrugs of 5-fluorouracil .2. Enzymatic degradation

被引:27
|
作者
Nichifor, M
Schacht, EH
Seymour, LW
机构
[1] STATE UNIV GHENT,DEPT ORGAN CHEM,BIOMAT & POLYMER RES GRP,B-9000 GHENT,BELGIUM
[2] UNIV BIRMINGHAM,SCH MED,DEPT CLIN ONCOL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND
关键词
5-fluorouracil; prodrug; collagenase; cathepsin; lysosomal enzyme;
D O I
10.1016/0168-3659(95)00141-7
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Polymeric conjugates of 5-fluorouracil were synthesized by the covalent attachment of oligopeptide chains, having a 2-(5-fluorouracil-1-yl)glycine ethyl ester residue at the C-terminus, to poly(ethylene glycol), dextran and poly[N-5-(2-hydroxyethyl)-L-glutamine]. In order to determine their ability to release the free drug by a specific enzymatic process catalyzed by proteinases occurring at the target site, the polymeric conjugates were incubated with three tumor-associated enzymes (collagenase, cathepsin B and cathepsin D) and a mixture of lysosomal enzymes. The enzymes hydrolysed to various extents one or two peptide bonds of the oligopeptide chains attached to polymer carriers. The position and rate of cleavage depended on the enzyme, the composition and configuration of the oligopeptide chain, and on the polymer carrier. PEG[Gly-Phe-Ala-Gly(FU)OEt](2) (1) conjugate was preferentially hydrolysed by collagenase, with the release of tripeptide Phe-Ala-Gly(FU)OR (1). PEG, dextran and PHEG conjugates having Gly-Phe-Gly-Gly(FU)OEt (l,d) as attached oligopeptide chain released free 5-FU in the presence of cathepsin B, with a rate determined by the polymeric carrier: PEG > PHEG > dextran. Finally, PEG conjugates with Gly-Phe-Gly-Gly(FU)OEt (I,d) and Gly-Phe-Phe-Gly(FU)OEt (d) chains released free 5-FU very rapidly in the presence of lysosomal enzymes.
引用
收藏
页码:79 / 92
页数:14
相关论文
共 50 条
  • [31] 5-FLUOROURACIL DERIVATIVES .2. CONVENIENT SYNTHESIS OF 5-FLUORO-2'-DEOXYURIDINE
    OZAKI, S
    KATAKAMI, T
    SANEYOSHI, M
    BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, 1977, 50 (08) : 2197 - 2198
  • [32] PRODRUGS OF 5-FLUOROURACIL .7. HYDROLYSIS KINETICS AND PHYSICOCHEMICAL PROPERTIES OF N-ETHOXYCARBONYLOXYMETHYL AND N-PHENOXYCARBONYLOXYMETHYL DERIVATIVES OF 5-FLUOROURACIL
    BUUR, A
    BUNDGAARD, H
    FALCH, E
    ACTA PHARMACEUTICA SUECICA, 1986, 23 (04): : 205 - 216
  • [33] Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil
    Watabe, T
    Okuda, H
    Ogura, K
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1997, 117 (10-11): : 910 - 921
  • [34] Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: experimental studies in pigs
    Laugesen, CS
    Steffansen, B
    Scherfig, E
    la Cour, M
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2005, 83 (02): : 184 - 190
  • [35] EFFECTS OF 5-FLUOROURACIL PRODRUGS ON THE CENTRAL NERVOUS-SYSTEM IN MICE AND RATS
    TOIDE, K
    UNEMI, N
    SEGAWA, T
    PHARMACEUTICAL RESEARCH, 1985, (02) : 83 - 86
  • [36] SYNTHESIS AND INVIVO ANTI-TUMOR ACTIVITY OF POTENTIAL 5-FLUOROURACIL PRODRUGS
    ROSOWSKY, A
    KIM, SH
    TRITES, D
    WICK, M
    JOURNAL OF MEDICINAL CHEMISTRY, 1982, 25 (09) : 1034 - 1040
  • [37] 5-FLUOROURACIL PRODRUGS SUSPENDED IN SILICONE OIL AS AN INTRAOCULAR SLOW RELEASE SYSTEM
    STEFFANSEN, B
    VERSTRAETEN, T
    HARTZER, M
    BLUMENKRANZ, M
    BUUR, A
    ASHTON, P
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1992, 33 (04) : 728 - 728
  • [38] Selective bone targeting 5-fluorouracil prodrugs: Synthesis and preliminary biological evaluation
    Ouyang, Liang
    He, Dongsheng
    Zhang, Jing
    He, Gu
    Jiang, Bo
    Wang, Qiang
    Chen, Zhengjun
    Pan, Junzhu
    Li, Yanhua
    Guo, Li
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (12) : 3750 - 3756
  • [39] SYNTHESIS AND INVIVO ANTI-TUMOR ACTIVITY OF POTENTIAL 5-FLUOROURACIL PRODRUGS
    ROSOWSKY, A
    KIM, SH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1982, 183 (MAR): : 77 - MEDI
  • [40] Pyrimidine degradation defects and severe 5-fluorouracil toxicity
    van Kuilenburg, A. B. P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 14 - 14